Skip to main content
Orchid Pharma Limited logo

Orchid Pharma Limited — Investor Relations & Filings

Ticker · ORCHPHARMA ISIN · INE191A01027 LEI · 33580076KIKCYSLZVF05 BSE.NS Manufacturing
Open in API
Filings indexed 448 across all filing types
Latest filing 2025-08-07 Regulatory Filings
Country IN India
Listing BSE.NS ORCHPHARMA

About Orchid Pharma Limited

https://www.orchidpharma.com/

Orchid Pharma Limited is a vertically integrated organization focused on the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company specializes in the anti-infectives segment, with a particular emphasis on cephalosporins and penicillins. Its operations span the entire value chain, including advanced research and development, process chemistry, and large-scale manufacturing. Orchid Pharma maintains facilities that adhere to rigorous international regulatory standards, enabling the supply of high-quality generic formulations and complex molecules to global markets. The company prioritizes innovation in chemical synthesis and formulation development to address complex therapeutic requirements and enhance healthcare outcomes through a robust portfolio of essential medicines.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an intimation of the schedule for an Analysts/Investors Earnings Call for the quarter ended June 30, 2025. It references Regulation 30 of SEBI and SEBI circulars, indicating a regulatory disclosure. The document does not contain actual financial results or detailed financial data but rather announces the timing and details of the upcoming earnings call. The length is under 5,000 characters and it serves as a notice for the call, not the call transcript or the earnings release itself. Therefore, it fits the category of a Call Transcript (CT) announcement but since it is only the schedule/intimation and not the transcript, the best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about the earnings call schedule.
2025-08-07 English
Credit Rating
Regulatory Filings
2025-08-07 English
Updates
M&A Activity Classification · 95% confidence The document is a brief announcement regarding the update on the purchase of assets of Allecra Therapeutics SAS by Orchid Pharma Limited. It references a court order and continuation of a previous intimation. The document is short (1366 characters) and serves as a notification of a transaction event rather than a detailed report or financial statement. It does not contain financial data, earnings, or detailed management discussion. The content fits best under a category related to merger or acquisition activity announcements. Given the nature of the asset purchase and court order, this aligns with M&A Activity (TAR) filings, which cover announcements related to merger proposals or takeover bids.
2025-08-05 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-08-05 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal notice from Orchid Pharma Limited to stock exchanges about a scheduled Board Meeting on August 12, 2025. The purpose of the meeting is to consider and approve the unaudited limited reviewed financial results for the quarter ended June 30, 2025. The document also mentions the closure of the trading window in relation to the financial results announcement. The document is short (2152 characters) and serves as an intimation or announcement of an upcoming event (Board Meeting and financial results approval), not the financial report itself. It does not contain actual financial data or detailed analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-08-05 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a formal disclosure submitted to stock exchanges referencing SEBI regulations, specifically Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements. It announces the purchase of assets of Allecra Therapeutics GmbH and Allecra Therapeutics SAS related to Enmetazobactam. The content focuses on the acquisition transaction and its strategic importance to the company. There are no financial statements, earnings data, or detailed financial analysis present. The document is an announcement of a capital transaction (asset purchase) rather than a full report or financial filing. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short (3055 characters), but it contains substantive information about the transaction, not just a notice of report publication or certification, so it is not RPA or RNS.
2025-07-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.